NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report.

The NOA-03 trial explored high-dose methotrexate alone in 37 patients with primary central nervous system lymphoma. The overall median survival was 25 months. After 4 years, the rate of leukoencephalopathy in patients surviving more than 12 months was 58% with and 10% without whole-brain radiotherap...

সম্পূর্ণ বিবরণ

গ্রন্থ-পঞ্জীর বিবরন
প্রধান লেখক: Herrlinger, U, Küker, W, Uhl, M, Blaicher, H, Karnath, H, Kanz, L, Bamberg, M, Weller, M
বিন্যাস: Journal article
ভাষা:English
প্রকাশিত: 2005

অনুরূপ উপাদানগুলি